Media & Press

  • Sodium Bicarbonate US Supply Agreement

    Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.

    January 2017

  • Phebra Welcomes PBS Listing for Leukaemia Treatment

    Phebra has welcomed the listing on the Australian PBS of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).

    April 2016

  • Clinical Trial for Jellyfish Sting Antidote

    Phebra is supporting a new clinical trial to test the efficacy of Magnesium Sulphate as an antidote for Irukandji Syndrome (IS), the acute pain caused by certain jellyfish stings.

    January 2015

  • Manufacturing and Product Supply Underway at New Phebra Plant

    Phebra’s manufacturing and product supply from its new sterile manufacturing plant is underway.

    February 2014

  • Australian Distribution of Syntometrine

    Phebra announces an agreement with Alliance Pharma to supply Syntometrine to the Australian market.

    September 2013

  • Phebra’s New Energy Efficiency Program

    Phebra is ‘going green’ and implementing an energy efficiency program at the new manufacturing plant. 

    June 2013

  • New Phebra Plant receives TGA manufacturing licence

    Phebra welcomes the granting of its licence from the TGA for its new sterile manufacturing plant

    May 2013

  • Industry and Innovation Minister Greg Combet Opens New Phebra Pharmaceutical Plant

    Federal Minister for Industry and Innovation, Greg Combet, officially opened and inspected Phebra’s new sterile manufacturing plant.

    March 2013

  • Phebra commences validation manufacturing at new plant

    The first stage of validation manufacturing at Phebra’s new plant begins

    December 2012

  • Phebra welcomes PBS listing of Naproxen

    Naproxen suspension is approved for reinbursement through the Pharmaceutical Benefits Scheme (PBS)

    November 2012